- Conditions
- Healthy, no Evidence of Disease
- Interventions
- Akt inhibitor SR13668
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 503
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Huntington Disease
- Interventions
- Time-Restricted Eating Diet
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- Drug · Diagnostic Test · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Working Memory
- Interventions
- Transcranial alternating current stimulation (tACS)
- Device
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
- Interventions
- CC-486, Vidaza
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
- Conditions
- Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
- Interventions
- Gastric Emptying Breath Test
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
- Interventions
- Gastric Ultrasound Exam
- Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more
- Conditions
- Drug Interactions, Neoplasms
- Interventions
- GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Fluoxetine Hydrochloride, PROZAC WEEKLY®
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Fasting, Delayed Gastric Emptying, Aspiration Pneumonia, Respiratory Aspiration of Gastric Content
- Interventions
- Gastric Ultrasound Baseline Scans, Acetaminophen Absorption Test (AAT), Gastric Ultrasound Serial Scans
- Diagnostic Test
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Metabolic Syndrome
- Interventions
- Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber
- Diagnostic Test · Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Basic Motor Learning Problem
- Interventions
- Attentional prime, Sham prime
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Adult Survivors of Childhood Leukemia
- Interventions
- individual diet & physical activity counselor and website through Healthways at Hopkins, self directed weight loss, questionnaires, fasting blood draw, measurement of height, weight and waist circumference, and blood pressure
- Behavioral · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Memphis, Tennessee
- Conditions
- Bicep Tendinitis, Biceps; Tenosynovitis, Bicipital Tendinitis, Left Shoulder, Bicipital Tendinitis, Right Shoulder, Bicipital Tendinitis, Unspecified Shoulder, Biceps Tendon Disorder
- Interventions
- Dry Needling, Heavy Slow Load Exercise, Rotator cuff and scapular stabilization exercise program, Soft tissue mobilization
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Boulder, Colorado
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- TRE plus SOC, SOC, TRE
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteers
- Interventions
- [11C]UCB-J, Brivaracetam, Levetiracetam
- Radiation · Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Urothelial Carcinoma
- Interventions
- Pembrolizumab, SBRT
- Drug · Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Interventions
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting
- Behavioral · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Postoperative Pain
- Interventions
- EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics
- Procedure
- Lead sponsor
- Bellaire Facial Surgery Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Houston, Texas • The Woodlands, Texas
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- 50 mg Usnoflast, 75 mg Usnoflast, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- La Jolla, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Visceral Obesity, Insulin Resistance
- Interventions
- Water-only fasting
- Other
- Lead sponsor
- TrueNorth Health Foundation
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 48 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Santa Rosa, California
- Conditions
- Cognitive Impairment, Dementia
- Interventions
- No interventions
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 1,892 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Healthy
- Interventions
- Losartan potassium/Hydrochlorothiazide
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy
- Interventions
- Mirtazapine 15 mg (Orally Disintegrating) Tablets, REMERON SolTab® 15 mg Orally Disintegrating Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota